Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland

• DOI: 10.1186/s13569-020-00131-x
• Publication Date: 2020-05-06T20:02:36Z
• Authors: Spyridon Gennatas; Florence Chamberlain; Thomas Carter; Susanna Slater; Elena Cojocaru; Beth Lambourn; Anna Stansfeld; Radha Todd; Mark Verrill; Nasim Ali; Robin L. Jones; Peter Simmonds; Nicola Keay; Heather McCarty; Sandra Strauss; Vassilios Karavas...; Palma Dileo; Charlotte Benson
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Research; 610; 3. Good health

A randomised phase II trial demonstrated that the addition of olaratumab to doxorubicin significantly increased overall survival (OS) in patients with advanced soft tissue sarcomas (STS) compared alone. The recently presented III study and sarcoma was discordant this finding.We performed a retrospective analysis adult advanced-/metastatic STS treated at least two cycles eight units across England Northern Ireland between May 2017 March 2019.172 were evaluable 40 (23.3%) had died time analysis. Median ECOG performance status (PS) 1. progression free (PFS) 6.8 months (95% CI 5.9-7.7 months). Leiomyosarcoma most common histological subtype (75 patients, 43.6%), followed by liposarcomas (19, 11.0%). mean number 5 (doxorubicin range 2-6; 2-23). Two (1.2%) complete response 34 (19.8%) partial response. 79 (45.9%) stable 58 (33.7%) progressive disease. 57 (33.1%) experienced grade ≥ 3 neutropenia 7 (4.1%) febrile neutropenia. Grade anaemia seen 21 (12.2%). non-haematological toxicities 35 (20.3%). clinically significant drop left ventricular ejection fraction 6 (3.5%). 48 (27.9%) required dose reduction. Overall is pending.Our results are keeping findings: rate, PFS OS similar those reported ANNOUNCE trial.